Toronto Dominion Bank Takes Position in Liquidia Co. (NASDAQ:LQDA)

Toronto Dominion Bank acquired a new stake in shares of Liquidia Co. (NASDAQ:LQDA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the company’s stock, valued at approximately $235,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of LQDA. Steward Partners Investment Advisory LLC bought a new position in shares of Liquidia during the fourth quarter valued at about $59,000. Summit Investment Advisors Inc. grew its stake in shares of Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after purchasing an additional 1,719 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in shares of Liquidia in the fourth quarter worth about $142,000. EntryPoint Capital LLC bought a new stake in shares of Liquidia in the fourth quarter worth about $154,000. Finally, Bayesian Capital Management LP bought a new stake in shares of Liquidia in the fourth quarter worth about $163,000. 64.54% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Jason Adair sold 1,856 shares of Liquidia stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the transaction, the insider now directly owns 184,304 shares in the company, valued at approximately $2,501,005.28. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rajeev Saggar sold 2,450 shares of Liquidia stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the transaction, the insider now owns 263,152 shares of the company’s stock, valued at $3,597,287.84. The trade was a 0.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,138 shares of company stock worth $450,233. Insiders own 26.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Wall Street Zen raised Liquidia from a “sell” rating to a “hold” rating in a research note on Thursday. Scotiabank reissued an “outperform” rating on shares of Liquidia in a research note on Monday, May 5th. Raymond James raised their target price on Liquidia from $27.00 to $29.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 9th. Needham & Company LLC reissued a “buy” rating and issued a $25.00 target price on shares of Liquidia in a research note on Wednesday. Finally, HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Monday, May 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Liquidia has an average rating of “Moderate Buy” and a consensus target price of $25.56.

Liquidia Stock Performance

Liquidia stock opened at $15.35 on Friday. The stock’s 50 day simple moving average is $14.74 and its two-hundred day simple moving average is $13.59. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -9.42 and a beta of 0.24. Liquidia Co. has a fifty-two week low of $8.26 and a fifty-two week high of $19.41.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. On average, analysts predict that Liquidia Co. will post -1.51 earnings per share for the current year.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).